Basics BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. IPO Date: August 1, 1999 Sector: Healthcare Industry: Biotech Market Cap: $11.09B Activated in VL: True Average Daily Range Avg Daily Range: $0.86 | 1.64% Avg Daily Range (30 D): $0.76 | 1.29% Avg Daily Range (90 D): $0.70 | 1.20% Institutional Daily Volume Avg Daily Volume: 1.2M Avg Daily Volume (30 D): 1.9M Avg Daily Volume (90 D): 1.73M Trade Size Avg Trade Size (Sh.): 105 Avg Trade Size (Sh.) (30 D): 57 Avg Trade Size (Sh.) (90 D): 57 Institutional Trades Total Inst.Trades: 23,613 Avg Inst. Trade: $3.54M Avg Inst. Trade (30 D): $3.96M Avg Inst. Trade (90 D): $4.59M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 5 Market Closing Trades Avg Closing Trade: $10.73M Avg Closing Trade (30 D): $17.17M Avg Closing Trade (90 D): $18.6M Avg Closing Volume: 133.15K     News Aug 19, 2025 @ 4:08 AM Predicting the Next Rule Breaker Buyout Source: Rick Munarriz Aug 5, 2025 @ 5:11 PM BioMarin Discontinues Preclinical Drug Candidate, ... Source: Vandana Singh Aug 4, 2025 @ 10:07 PM BioMarin (BMRN) Q2 Revenue Jumps 16% Source: Jesterai Jun 20, 2025 @ 9:00 PM Inozyme Pharma, Inc. Announces Postponement of 202... Source: N/A Jun 5, 2025 @ 7:06 AM Here Are All 6 Stocks I've Bought Through 5 Months... Source: Sean Williams Financials   TTM Q2 2025 Q1 2025 Basic EPS $3.45 $1.25 $.97 Diluted EPS $3.39 $1.23 $.95 Revenue $ 3.06B $ 825.41M $ 745.15M Gross Profit $ 2.44B $ 675.32M $ 593.59M Net Income / Loss $ 657.24M $ 240.53M $ 185.69M Operating Income / Loss $ 776.08M $ 276.89M $ 223.89M Cost of Revenue $ 626.24M $ 150.09M $ 151.56M Net Cash Flow $ 246.54M $ 168.08M $ 107.38M PE Ratio 16.57